Liquidia Co. (NASDAQ:LQDA) Receives Consensus Rating of “Buy” from Analysts

Shares of Liquidia Co. (NASDAQ:LQDA) have been assigned a consensus rating of “Buy” from the nine analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $25.38.

LQDA has been the topic of a number of analyst reports. Wells Fargo & Company initiated coverage on Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price objective on shares of Liquidia in a research note on Thursday, November 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price objective on shares of Liquidia in a research note on Thursday. Lifesci Capital began coverage on Liquidia in a research report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 target price on the stock. Finally, Scotiabank began coverage on Liquidia in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 target price on the stock.

Insider Activity at Liquidia

In other news, CEO Roger Jeffs sold 8,053 shares of the business’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $89,468.83. Following the sale, the chief executive officer now owns 812,193 shares of the company’s stock, valued at approximately $9,023,464.23. The trade was a 0.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Rajeev Saggar sold 2,260 shares of the business’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $25,108.60. Following the completion of the sale, the insider now directly owns 207,383 shares in the company, valued at $2,304,025.13. This represents a 1.08 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,007 shares of company stock worth $245,780 in the last 90 days. 30.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Liquidia

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Whitcomb & Hess Inc. raised its position in shares of Liquidia by 10.2% during the third quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock worth $116,000 after purchasing an additional 1,074 shares during the period. Arizona State Retirement System grew its holdings in shares of Liquidia by 10.7% during the second quarter. Arizona State Retirement System now owns 13,842 shares of the company’s stock valued at $166,000 after buying an additional 1,341 shares in the last quarter. Quest Partners LLC purchased a new position in shares of Liquidia during the second quarter valued at $27,000. Profund Advisors LLC grew its holdings in shares of Liquidia by 31.6% during the second quarter. Profund Advisors LLC now owns 14,434 shares of the company’s stock valued at $173,000 after buying an additional 3,466 shares in the last quarter. Finally, DMC Group LLC grew its holdings in shares of Liquidia by 36.7% during the third quarter. DMC Group LLC now owns 13,883 shares of the company’s stock valued at $139,000 after buying an additional 3,725 shares in the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Stock Performance

NASDAQ:LQDA opened at $12.19 on Friday. The stock has a market capitalization of $1.03 billion, a price-to-earnings ratio of -7.48 and a beta of 0.23. Liquidia has a 1 year low of $8.26 and a 1 year high of $16.99. The stock has a fifty day moving average price of $11.13 and a two-hundred day moving average price of $11.04.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).